UFP-101

UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pKi of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect[1][2].

[C@H](CC1=CC=CC=C1)(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCC(N)=O)C(N)=O)=O)CC(N)=O)=O)CCCCN)=O)CCCNC(=N)N)=O)CCCCN)=O)CCCNC(=N)N)=O)C)=O)CO)=O)CCCCN)=O)CCCNC(=N)N)=O)C)=O)=O)[C@@H](C)O)=O)NC(CNC(CNC(CNCC2=CC=CC=C2)=O)=O)=O

[1]Calo G, et al. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol. 2002;136(2):303-311.|[2]Gavioli EC, et al. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci. 2003;17(9):1987-1990.